1 June 2026 - Celltrion announced on Monday that it has submitted a regulatory application to Health Canada for CT-P55, its biosimilar candidate to Cosentyx (secukinumab), a blockbuster treatment for autoimmune diseases.

The company is seeking approval for all indications currently held by the reference product in Canada, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.

Read Korea Biomedical Review article